Influx and efflux transporters contribute to the increased dermal exposure to active metabolite of regorafenib after repeated oral administration in mice, AL-SHAMMARI Aya Hasan;MASUO Yusuke;FUJITA Ken-ichi;YOSHIKAWA Yuka;NAKAMICHI Noritaka;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, J Pharm Sci, 108(6):2173 - 2179, Jun. 2019, Peer-reviewed
Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38., Iwase Mariko;Fujita Ken-Ichi;Nishimura Yuki;Seba Natsumi;Masuo Yusuke;Ishida Hiroo;Kato Yukio;Kiuchi Yuji, Cancer chemotherapy and pharmacology, 83(5):993 - 998, May 2019, Peer-reviewed
123I-iomazenil whole-body imaging to detect hepatic carboxylesterase drug-metabolizing enzyme activity, MIZUTANI Asuka;KOBAYASHI Masato;FUJITA Ken-ichi;TAKAHASHI Kotaro;HOKAMA Tsuzumi;TAKASU Hiroaki;NISHI Kodai;NISHII Ryuichi;SHIKANO Naoto;FUKUCHI Kazuki;KAWAI Keiichi, Nucl Med Commun, 39(9):825 - 833, Sep. 2018, Peer-reviewed
Efficacy and Safety of Long-acting Beta-2 Agonist and Long-acting Muscarinic Antagonist Combinations in Patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Phase 3 Randomized Trials, ANDO Koichi;TANAKA Akihiko;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci,
30(2):159 - 174, Jun. 2018, Peer-reviewed,
DOI:10.15369/sujms.30.159 Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis, MANABE Ryo;ANDO Koichi;KUSUMOTO Sojiro;TANAKA Akihiko;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori, Showa Univ J Med Sci, 30(2):309 - 315, Jun. 2018, Peer-reviewed
Development of evaluation method for the potential of OATP1B-mediated DDI using endogenous conpounds, 楠原 洋之;森 大輝;藤田 健一;佐々木 康綱;杉山 雄一, 臨床薬理の進歩, (39):57 - 65, Jun. 2018, Not refereed
Comparative Efficacy and Safety of Anti-Interleukin-5 Therapies and Placebo in Patients with Uncontrolled Eosinophilic Asthma:A Systematic Review and Meta-analysis of Phase 3 Trials, ANDO Koichi;TANAKA Akihiko;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;OHMORI Tohru;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci,
30(1):11 - 25, Mar. 2018, Peer-reviewed,
DOI:10.15369/sujms.30.11 A Long-acting Muscarinic Antagonist (LAMA) Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-analysis of Randomized Trials, ANDO Koichi;TANAKA Akihiko;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci,
30(1):1 - 9, Mar. 2018, Peer-reviewed,
DOI:10.15369/sujms.30.1 Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib, ELLAWATTY Waleed Elsayed Ahmed;MASUO Yusuke;FUJITA Ken-ichi;YAMAZAKI Erina;ISHIDA Hiroo;ARAKAWA Hiroshi;NAKAMICHI Noritaka;ABDELWAHED Ramadan;SASAKI Yasutsuna;KATO Yukio, Drug Metab Dispos, 46(1):33 - 40, Jan. 2018, Peer-reviewed
EGFR-TKI Versus Chemotherapy for Previously Untreated Advanced Non-Small Cell Lung Cancer in Asians: A Meta-Analysis, ANDO Koichi;KUSUMOTO Sojiro;TANAKA Akihiko;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci,
29(4):435 - 443, Dec. 2017, Peer-reviewed,
DOI:10.15369/sujms.29.435 Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms, YAMAOKA Toshimitsu;OHBA Motoi;OHMORI Tohru, Int J Mol Sci, 18(11):2420, Nov. 2017, Peer-reviewed
薬効別にみた薬物動態と臨床でのポイント 細胞障害性抗がん薬, 藤田 健一, 薬事, 59(14):3004 - 3011, Oct. 2017, Not refereed
A Comparison of Adverse Effect Profiles of Two Anti-IL-5 Therapies in Adults with Uncontrolled Asthma―A Network Meta-analysis of Phase 3 Trials―, ANDO Koichi;MIYATA Yoshito;HIRAI Kuniaki ;MIZUMA Hiroko ;YAMAGUCHI Munehiro;MURATA Yasunori;HOMMA Tetsuya;OHTA Shin;YAMAMOTO Mayumi;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;YOKOE Takuya;OHNISHI Tsukasa;OHMORI Tohru;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 29(3):279 - 287, Sep. 2017, Peer-reviewed
Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, FUJITA Ken-ichi;MASUO Yusuke;YAMAZAKI Erina;SHIBUTANI Toshiki;KUBOTA Yutaro;NAKAMICHI Noritaka;SASAKI Yasutsuna;KATO Yukio, J Pharm Sci, 106(9):2632 - 2641, Sep. 2017, Peer-reviewed
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure., YAMAOKA Toshimitsu;OHBA Motoi;ARATA Satoru;OHMORI Tohru, J Vis Exp, (126):e, Aug. 2017, Peer-reviewed
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;MURATA Yasunori;KUSUMOTO Sojiro;ANDO Koichi;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, Mol Cancer Res, 15(7):915 - 928, Jul. 2017, Peer-reviewed
Comprehensive microRNA-SNPs analysis in Japanese for optimized cancer pharmacotherapy, 中島 美紀;藤田 健一;佐々木 康綱, 臨床薬理の進歩, (38):121 - 128, Jun. 2017, Not refereed
Comparing the Adverse Event Profiles of Nivolumab and Docetaxel in Previously-treated or Refractory Advanced Non-small Cell Lung Cancer: A Meta-analysis of Two Phase 3 Trials, ANDO Koichi;MURATA Yasunori;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;YOKOE Takuya;OKUDA Kentaro ;OHNISHI Tsukasa;INOUE Shin;OHMORI Tohru;SAGARA Hironori, Showa Univ J Med Sci,
29(1):69 - 77, Mar. 2017, Peer-reviewed,
DOI:10.15369/sujms.29.69 Toxicities of receptor tyrosine kinase inhibitors in cancer pharmacotherapy: management with clinical pharmacology, FUJITA Ken-ichi;ISHIDA Hiroo;KUBOTA Yutaro;SASAKI Yasutsuna, Curr Drug Metab, 18(3):186 - 198, Mar. 2017, Peer-reviewed
Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation., YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;KISHINO Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;HIROSE Takashi;OHNISHI Tsukasa;SASAKI Yasutsuna, Mol Cancer Ther, 15(12):3040 - 3054, Dec. 2016, Peer-reviewed
Long-term prognostic impact of circulating tumour cells in gastric cancer patients., ITO Hiroaki;SATO Jun;TSUJINO Yukio;YAMAGICHI Noriko;KIMURA Satoshi;GOHDA Keigo;MURAKAMI Katsuhiro;ONIMARU Manabu;OHMORI Tohru;ISHIKAWA Fumihiro;INOUE Haruhiro, World J Gastroenterol, 22(46):10232 - 10241, Dec. 2016, Peer-reviewed
Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer., ITO Hiroaki;YAMAGUCHI Noriko;ONIMARU Manabu;KIMURA Satoshi;OHMORI Tohru;ISHIKAWA Fumihiro;SATO Jun;ITO Shun;INOUE Haruhiro, Oncol Lett, 12(6):4720 - 4726, Dec. 2016, Peer-reviewed
Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan., TAKATA Kosuke;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;ICHIKAWA Wataru;SHIMADA Ken;SEKIKAWA Takashi;TAKI-TAKEMOTO Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, J Pharm Health Care Sci, 2(30):1 - 9, Nov. 2016, Peer-reviewed
Investigation of bioequivalence between brand-name and generic irinotecan products., SAITO Ken-ichi;INOUE Yutaka;IKEGAMI Yoji;NANBO Izumi;ONOZUKA Mari;SANO Kazumi;YOSHIDA Hisahiro;SAKAMOTO Toshihiro;TATEBAYASHI Emi;FUJITA Ken-ichi;SASAKI Yasutsuna;KITAZAWA Takaki, Anticancer Res, 39(11):5957 - 5963, Nov. 2016, Peer-reviewed
Over 80歳のがん診療とその臨床的課題 併存疾患を有する高齢がん患者への対応 polypharmacy, 藤田 健一, Cancer Board Square, 2(2):280 - 284, Jul. 2016, Not refereed
HILIC-MS/MS法によるヒト涙液中tegafurおよび5-fluorouracilの高感度分析法, 小渕 律子;李 暁鵬;石田 博雄;熊澤 武志;池田 賢一郎;藤城 雅也;藤田 健一;佐藤 淳一;澤口 聡子;高橋 春男;佐藤 啓造, 昭和学士会雑誌, 76(3):299 - 307, Jun. 2016, Peer-reviewed
Bioequivalence studies of a generic formulation (SW651K) to the brand drug S-1 in tumor-bearing rat models, OKABE Tomoyuki;OGURA Takeharu;YOSHIMURA Takashi;TANAKA Yoshiyuki;TOYODA Hiromu;FUJITA Ken-ichi;SASAKI Yasutsuna, J Bioequiv Availab, 8(3):112 - 117, May 2016, Peer-reviewed
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer, HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OKUDA Kentaro;OHMORI Tohru;SASAKI Yasutsuna, Lung Cancer, 93:69 - 76, Mar. 2016, Peer-reviewed
Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure, FUJITA Ken-ichi;MASUO Yusuke;OKUMURA Hidenori;WATANABE Yusuke;SUZUKI Hiromichi;SUNAKAWA Yu;SHIMADA Ken;KAWARA Kaori;AKIYAMA Yuko;KITAMURA Masanori;KUNISHIMA Munetaka;SASAKI Yasutsuna;KATO Yukio, Pharm Res,
33(2):269 - 282, Feb. 2016, Peer-reviewed,
DOI:10.1007/s11095-015-1785-0 Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction, SHIBATA Takashi;EBATA Tomoki;FUJITA Ken-ichi;SHIMOKATA Tomoya;MAEDA Osamu;MITSUMA Ayako;SASAKI Yasutsuna;NAGINO Masato;ANDO Yuichi, Cancer Sci, 107(2):168 - 172, Feb. 2016, Peer-reviewed
Atypical pharmacokinetics and toxicity of irinotecan hydrochloride in cancer patients with severe renal failure who were undergoing dialysis, 藤田 健一, 日本透析医会雑誌, 30(3):538 - 542, Dec. 2015, Peer-reviewed
Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells, TOBA-ICHIHASHI Yoko;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi, Biochem Biophys Rep, 5:1 - 7, Nov. 2015, Peer-reviewed
Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells., TOBA-ICHIHASHI Yoko;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi, Biochem Biophys Rep, 5:1 - 7, Nov. 2015, Peer-reviewed
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer, FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;SASAKI Yasutsuna, World J Gastroenterol, 21(43):12234 - 12248, Nov. 2015, Peer-reviewed
A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer, FUJITA Ken-ichi;YOSHINO Etsuko;KAWARA Kaori;MAEDA Kazuya;KUSUHARA Hiroyuki;SUGIYAMA Yuichi;YOKOYAMA Taro;KANETA Toshikado;ISHIDA Hiroo;SASAKI Yasutsuna, Cancer Chemother Pharmacol,
76(4):793 - 801, Oct. 2015, Peer-reviewed,
DOI:10.1007/s00280-015-2844-2 Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology, AMEMIYA Takahiro;HONMA Masashi;KARIYA Yoshiaki;GHOSH Samik;KITANO Hiroaki;KURACHI Yoshihisa;FUJITA Ken-ichi;SASAKI Yasutsuna;HOMMA Yukio ;ABERNETHY Darrel;KUME Haruki;SUZUKI Hiroshi, NPJ Syst Biol Appl,
1:e15005, Sep. 2015, Peer-reviewed,
DOI:10.1038/npjsba.2015.5 Role of protein kinase C-η in cigarette smoke extract-induced apoptosis in MRC-5-cells., SON ES;KYUNG SY;LEE SP;JEONG SH;SHIN JY;OHBA Motoi;YEO EJ;PARK JW, Hum Exp Toxicol, 34(9):869 - 877, Sep. 2015, Peer-reviewed
Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?, SASAKI Yasutsuna;HAMADA Kazuyuki;KANETA Toshikado;TAKAHASHI Takehiro;KUBOTA Yutaro;ISHIDA Hiroo;ICHIKAWA Wataru, Cancer Sci, 106(8):1100, Aug. 2015, Peer-reviewed
Improved Long-term Culture of Epidermal Stem Cells Utilizing CD200R-expressing Feeder Cells, TOYA Etsuko;OHBA Motoi, Showa Univ J Med Sci,
27(2):83 - 91, Jun. 2015, Peer-reviewed,
DOI:10.15369/sujms.27.83 Silver Nanoscale Hexagonal Column Chips for Detecting Cell-free DNA and Circulating Nucleosomes in Cancer Patients., ITO Hiroaki;HASEGAWA Katsuyuki;HASEGAWA Yuuki;NISHIMAKI Tadashi;HOSOMICHI Kazuyoshi;KIMURA Satoshi;OHBA Motoi;YAO Hiroshi;ONIMARU Manabu;INOUE Itsuro;INOUE Haruhiro, Sci Rep, 5:10455, May 2015, Peer-reviewed
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients., ICHIKAWA Wataru;UEHARA Keisuke;MINAMIMURA Keisuke;TANAKA Chihiro;TAKII Yasumasa;MIYAUCHI Hideaki;SADAHIRO Sotaro;FUJITA Ken-ichi;MORIWAKI Toshikazu;NAKAMURA Masato;TAKAHASHI Takehiro;TSUJI Akihito;SHINOZAKI Katsunori;MORITA Satoshi;ANDO Yuichi;OKUTANI Yukihiro;SUGIHARA Masahiro;SUGIYAMA Toru;OHASHI Yasuo;SAKATA Yuh, Br J Cancer, 112(10):1709 - 1716, May 2015, Peer-reviewed
In Vivo Radioactive Metabolite Analysis for Individualized Medicine: A Basic Study of a New Method of CYP Activity Assay using 123I-IMP., NISHI Kodai;MIZUTANI Asuka;SHIKANO Naoto;FUJITA Ken-ichi;KOBAYASHI Masato;ONO Masahiro;NISHII Ryuichi;SASAKI Yasutsuna;KINUYA Seigo;KAWAI Keiichi, Nucl Med Biol, 42(2):171 - 176, Feb. 2015, Peer-reviewed
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer., FUJITA Ken-ichi;HIROSE Takashi;KUSUMOTO Sojiro;SUGIYAMA Tomohide;SHIRAI Takao;NAKASHIMA Masanao;AKIYAMA Yuko;SASAKI Yasutsuna, Lung Cancer, 86(1):113 - 114, Oct. 2014, Peer-reviewed
No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion., KANETA Toshikado;FUJITA Ken-ichi;AKIYAMA Yuko;KAWARA Kaori;SUNAKAWA Yu;KAWACHI Asuka;SHIMADA Ken;SASAKI Yasutsuna, Cancer Chemother Pharmacol, 74(3):539 - 547, Sep. 2014, Peer-reviewed
Prognostic impact of the number of viable circulating cells with high telomerase activity in gastric cancer patients: A prospective study, ITO Hiroaki;INOUE Haruhiro;KIMURA Satoshi;OHMORI Tohru;ISHIKAWA Fumihiro;GOHDA Keigo;SATO Jun, Int J Oncol, 45(1):227 - 234, Jul. 2014, Peer-reviewed
Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer., ISHIDA Koko;HIROSE Takashi;YOKOUCHI Junichi ;OKI Yasunari;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHNISHI Tsukasa;OHMORI Tohru;KAGAMI Yoshikazu, Mol Clin Oncol, 2(3):405 - 410, May 2014, Peer-reviewed
Atypical pharmacokinetics of anticancer drug mainly eliminated via the liver in cancer patients with severe renal failure., 藤田 健一, ファルマシア, 50(4):300 - 304, Apr. 2014, Peer-reviewed
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world', FUJITA Ken-ichi;SASAKI Yasutsuna, Drug Metab Pharmacokinet, 29(1):20 - 28, Jan. 2014, Peer-reviewed
Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans, FUJITA Ken-ichi;SUGIURA Tomoko;OKUMURA Hidenori;UMEDA Saki;NAKAMICHI Noritaka;WATANABE Yusuke;SUZUKI Hiromichi;SUNAKAWA Yu;SHIMADA Ken;KAWARA Kaori;SASAKI Yasutsuna;KATO Yukio, Pharm Res, 31(1):204 - 215, Jan. 2014, Peer-reviewed
腎機能障害患者における抗がん薬の薬物動態、抗がん薬による腎機能障害, 藤田 健一, 月刊薬事, 55(13):2341 - 2345, Dec. 2013, Not refereed
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer., SASAKI Tetsuya;FUJITA Ken-ichi;SUNAKAWA Yu;ISHIDA Hiroo;YAMASHITA Keishi;MIWA Keisuke;SAJI Shigehira;KATO Yasuhisa;SASAKI Yasutsuna, Int J Clin Oncol, 18(4):735 - 742, Aug. 2013, Peer-reviewed
Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease., OKUDA Kentaro;HIROSE Takashi;OKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHNISHI Tsukasa;OHMORI Tohru, Anticancer Res, 32(12):5475 - 5480, Dec. 2012, Peer-reviewed
進行再発非小細胞肺癌に対するセカンドライン化学療法の検討, 白井 崇生;廣瀬 敬;村田 泰規;大木 康成;楠本 壮二郎;杉山 智英;石田 博雄;中嶌 賢尚;大西 司;山岡 利光;大森 亨;奥田 健太郎, 昭和医学会雑誌,
72(4):446 - 452, Aug. 2012, Peer-reviewed,
DOI:10.14930/jsma.72.446 Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer., HIROSE Takashi;MURATA Yasunori;OKI Yasunari;SUGIYAMA Tomohide;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masano;山岡 利光;OKUDA Kentaro;OHNISHI Tsukasa;OHMORI Tohru, Oncol Res, 20(2月3日):131 - 137, Feb. 2012, Peer-reviewed
ヒト三次元培養皮膚への遺伝子導入法の確立と表皮分化へのCキナーゼの関与, 上岡 なぎさ;本間 生夫;赤羽 智子;河野 葉子;飯島 正文;大場 基, 昭和医学会雑誌,
70(3):253 - 262, Jun. 2010, Peer-reviewed,
DOI:10.14930/jsma.70.253
AUC of unbound form of regorafenib active metabolites M2 and M5 are associated with hand-foot syndrome, and ABCG2 polymorphism in Japanese patients with colorectal cancer, FUJITA Ken-ichi;KUBOTA Yutaro;MASUO Yusuke;ISHIDA Hiroo;KATO Yukio;SASAKI Yasutsuna, 120th American Society for Clinical Pharmacology and Therapeutics annual meeting, 14 Mar. 2019, Washington DC
T790M-EGFRによりアファチニブ耐性をきたした肺腺癌細胞株におけるロシレチニブ耐性機序の検討, 山岡 利光;楠本 壮二郎;安藤 浩一;石田 博雄;大西 司;相良 博典;大森 亨, 第59回日本肺癌学会学術集会, 30 Nov. 2018, 東京
Cytotoxic effects of tyrosine kinase inhibitors in keratinocytes and their possible relevance to ABC transporters, SHIMADA Kazuhiro;MASUO Yusuke;FUJITA Ken-ichi;SASAKI Yasutsuna;KATO Yukio, 2018 International Meeting on 22nd MDO and 33rd JSSX, 04 Oct. 2018, Kanazawa
Accumulation of active metabolite of anticancer agent regorafenib involves nonlinear hepatic distribution after repeated dose, AL-SHAMMARI Aya Hasan;MASUO Yusuke;FUJITA Ken-ichi;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, 2018 International Meeting on 22nd MDO and 33rd JSSX, 04 Oct. 2018, Kanazawa
Effects of severe renal failure on drug disposition and response, FUJITA Ken-ichi, 2018 International Meeting on 22nd MDO and 33rd JSSX, 02 Oct. 2018, Kanazawa
Evolution of kinase inhibitors sensitivity in three-dimensional suspended spheroid culture platform, ITO Risa;SUZUKI Toshihiro;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;OGASAWARA Yuki, 第77回日本癌学会学術総会, 28 Sep. 2018, 大阪
Mechanism of resistance to third-generation EGFR-TKI, rociletinib, in lung adenocarcinoma cells with EGFR-T790M mutation, YAMAOKA Toshimitsu;NAKATANI Kaori;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;IWAI Shinichi;OHMORI Tohru, 第77回日本癌学会学術総会, 28 Sep. 2018, 大阪
10-methyl-aplog-1 enhances the cytotoxic effects of HDAC inhibitor in esophageal squamous carcinoma cells, OHBA Motoi;TOYA Etsuko;ARATA Satoru;YAMAOKA Toshimitsu;IRIE Kazuhiro;SASAKI Yasutsuna, 第16回日本臨床腫瘍学会学術集会, 21 Jul. 2018, 神戸
Assessment of paclitaxel-induced OATP1B inhibition in patients with non-small cell cancer by using endogenous substrates, FUJITA Ken-ichi;MORI Daiki;ISHIDA Hiroo;MIZUNO Tadahaya;MAEDA Kazuya;SASAKI Yasutsuna;KUSUHARA Hiroyuki, 第16回日本臨床腫瘍学会学術集会, 19 Jul. 2018, 神戸
Resistance mechanisms to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in lung adenocarcinoma cells harboring the EGFR-T790M mutation, NAKATANI Kaori;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;FUJITA Ken-ichi;TAKI Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, 18th World Congress of Basic and Clinical Pharmacology (WCP2018), 05 Jul. 2018, Kyoto
Resistance mechanisms to third-generation EGFR TKIs in lung adenocarcinoma harboring EGFR T790M mutation, 中谷 香織;山岡 利光;大森 亨;大場 基;藤田 健一;滝 伊織;亀井 大輔;岩井 信市, 日本薬学会第138年会, 28 Mar. 2018, 金沢
内在性基質をプローブとした抗がん剤パクリタキセルによるOATP1B阻害の検出, 森 大輝;石田 博雄;水野 忠快;藤田 健一;楠本 壮二郎;前田 和哉;佐々木 康綱;楠原 洋之, 第38回日本臨床薬理学会学術総会, 09 Dec. 2017, 横浜
有機カチオントランスポーター1はチロシンキナーゼ阻害薬であるパゾパニブの肝取り込みに関与する, 藤田 健一;ELLAWATTY Waleed EA;増尾 友佑;石田 博雄;佐々木 康綱;加藤 将夫, 第38回日本臨床薬理学会学術総会, 08 Dec. 2017, 横浜
薬剤師が関与する臨床試験(シンポジウム), 藤田 健一, 第38回日本臨床薬理学会学術総会, 07 Dec. 2017, 横浜
Characterization of OATP1B1 inhibition by indole metabolites, SEBA Natsumi;MASUO Yusuke;FUJITA Ken-ichi;NAKAMICHI Noritaka;SASAKI Yasutsuna;KATO Yukio, 日本薬物動態学会第32回年会, 29 Nov. 2017, 東京
Assessment of drug-drug interaction potency against OATP1B with paclitaxel using an endogenous substrate as an alternative probe, MORI Daiki;ISHIDA Hiroo;MIZUNO Tadahaya;FUJITA Ken-ichi;KUSUMOTO Sojiro;MAEDA Kazuya;SASAKI Yasutsuna;KUSUHARA Hiroyuki, 日本薬物動態学会第32回年会, 29 Nov. 2017, 東京
Involvement of ABC drug transporters in disposition of tyrosine kinase inhibitor regorafenib and its active metabolites after repeated oral dose, HASAN Aya;MASUO Yusuke;FUJITA Ken-ichi;YAMAZAKI Erina;KUBOTA Yutaro;NAKAMICHI Noritaka;SASAKI Yasutsuna;KATO Yukio, 日本薬物動態学会第32回年会, 29 Nov. 2017, 東京
Keratinocyteにおける膜輸送体の発現とレゴラフェニブ分布に及ぼす影響, 島田 和弘;増尾 友佑;藤田 健一;山﨑 絵里名;久保田 祐太郎;中道 範隆;佐々木 康綱;加藤 将夫, 日本薬学会北陸支部第129回例会, 26 Nov. 2017, 金沢
Organic cation transporter 1 is involved in hepatic uptake of pazopanib in humans, FUJITA Ken-ichi;MASUO Yusuke;ISHIDA Hiroo;SASAKI Yasutsuna;KATO Yukio, 第76回日本癌学会学術総会, 30 Sep. 2017, 横浜
10-methyl-aplog-1 augments the therapeutic efficacy of HDAC inhibitor in esophageal squamous carcinoma cells, 大場 基;外谷 衣都子;荒田 悟;山岡 利光;入江 一浩;佐々木 康綱, 第76回日本癌学会学術総会, 28 Sep. 2017, 横浜
Involvement of ABC transporters in tissue distribution and disposition of active metabolites of regorafenib, FUJITA Ken-ichi;YAMAZAKI Erina;MASUO Yusuke;NAKAMICHI Noritaka;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, 第15回日本臨床腫瘍学会学術集会, 27 Jul. 2017, 神戸
Involvement of organic cation transporter 1 in hepatic uptake of pazopanib in humans, ISHIDA Hiroo;ELLAWATTY Waleed Elsayed Ahmed;FUJITA Ken-ichi;MASUO Yusuke;KATO Yukio;SASAKI Yasutsuna, 第15回日本臨床腫瘍学会学術集会, 27 Jul. 2017, 神戸
日本における大腸がん術後補助化学療法のレジメン別医療経済評価, 髙田 昂輔;藤田 健一;滝 伊織;亀井 大輔;佐々木 康綱;岩井 信市, 日本薬学会第137年会, 25 Mar. 2017, 仙台
Unfit症例におけるがん薬物療法の至適化と臨床薬理学:腎障害がん患者におけるイリノテカンの特異な体内動態と投与法, 藤田 健一, 第37回日本臨床薬理学会学術総会, 02 Dec. 2016, 米子
レゴラフェニブと活性代謝物の体内動態解析とABC輸送担体の関与, 藤田 健一;増尾 友佑;山崎 絵里名;澁谷 俊紀;中道 範隆;佐々木 康綱;加藤 将夫, 第37回日本臨床薬理学会学術総会, 01 Dec. 2016, 米子
Involvement of ABC drug transporters in disposition of active metabolites of tyrosine kinase inhibitor regorafenib, YAMAZAKI Erina;MASUO Yusuke;FUJITA Ken-ichi;SHIBUTANI Toshiki;NAKAMICHI Noritaka;SASAKI Yasutsuna;KATO Yukio, 日本薬物動態学会第31回年会, 14 Oct. 2016, 松本
Inhibition of human hepatic transporter OATP1B1 by indole metabolites, 清波 夏実;増尾 友佑;藤田 健一;中道 範隆;佐々木 康綱;加藤 将夫, 日本薬物動態学会第31回年会, 14 Oct. 2016, 松本
Dual resistance of EGFR-mutant lung adenocarcinoma cells to EGFR and MET inhibitors, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, 第75回日本癌学会学術総会, 08 Oct. 2016, 横浜
Roles of BCRP and P-gp in disposition of regorafenib and active metabolites M-2 and M-5, FUJITA Ken-ichi;MASUO Yusuke;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, 第75回日本癌学会学術総会, 08 Oct. 2016, 横浜
Combination effect of afatinib and BI836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC, OHMORI Tohru;YAMAOKA Toshimitsu;ARATA Satoru;OHBA Motoi;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;HIROSE Takashi;ONISHI Tsukasa;NISHIO Kazuto, 第75回日本癌学会学術総会, 07 Oct. 2016
Mathematical analysis of the role of CADM1 in the MET-driven resistance against gefitinib in lung adenocarcinoma, ITO Takeshi;OHBA Motoi;SUZUKI Takashi;MURAKAMI Yoshinori, 第75回日本癌学会学術総会, 06 Oct. 2016, 横浜
大腸がん術後補助化学療法レジメンの医療経済性の検討, 髙田 昂輔;藤田 健一;滝 伊織;亀井 大輔;佐々木 康綱;岩井 信市, 第26回日本医療薬学会年会, 18 Sep. 2016, 京都
Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells, 山岡 利光, 第14回日本臨床腫瘍学会学術集会, 28 Jul. 2016, 神戸
Delayed elimination of SN-38 in cancer patients with severe renal failure: mechanism and appropriate irinotecan dose, FUJITA Ken-ichi, 第14回日本臨床腫瘍学会学術集会, 28 Jul. 2016, 神戸
腎機能低下がん患者における特異なSN-38の体内動態とPBPKモデル, 藤田 健一, 医療薬学フォーラム2016/第24回クリニカルファーマシーシンポジウム, 25 Jun. 2016, 大津
The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyotaka;OGASAWARA Yuki, AACR Annual Meeting 2016, 18 Apr. 2016, New Orleans
Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, American Association for Cancer Research Annual Meeting 2016, 18 Apr. 2016, New Orleans
Combination effect of afatinib and BI 836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC cells, OHMORI Tohru;YAMAOKA Toshimitsu;ARATA Satoru;OHBA Motoi;MURATA Yasunori;KISHIDA Yasunari;KUSUMOTO Sojiro;NAKASHIMA Masanao;HIROSE Takashi;OHNISHI Tsukasa;NISHIO Kazuto, American Association for Cancer Research Annual Meeting 2016, 18 Apr. 2016, New Orleans
日本人の抗がん薬投与における認知機能評価法の確立に向けた検討, 髙田 昂輔;石井 麻菜;竹本 伊織;亀井 大輔;藤田 健一;佐々木 康綱;岩井 信市, 日本薬学会第136年会, 27 Mar. 2016, 横浜
抗がん薬のリバーストランスレーショナルリサーチ:至適な薬物療法を目指して, 藤田 健一, 第18回 北海道大学薬学部 生涯教育特別講座 冬季講演会, 20 Feb. 2016, 札幌
極めて腎機能の低下したがん患者におけるイリノテカン塩酸塩の至適投与量の推定, 藤田 健一;増尾 友祐;奥村 英典;佐々木 康綱;加藤 将夫, 第36回日本臨床薬理学会学術総会, 10 Dec. 2015, 東京
抗悪性腫瘍薬パゾパニブのUDP-グルクロン酸転移酵素(UGT)1A1に対する阻害効果, 岩瀬 万里子;藤田 健一;西村 有希;小口 勝司, 第36回日本臨床薬理学会学術総会, 10 Dec. 2015, 東京
日本人を対象とした認知機能の評価法の検証, 髙田 昂輔;石井 麻菜;竹本 伊織;亀井 大輔;藤田 健一;佐々木 康綱;岩井 信市, 第62回昭和大学学士会総会, 28 Nov. 2015, 東京
UFLC-MS/MS法によるヒト涙液中tegafur及び5-fluorouracilの高感度分析法, 小渕 律子;李 暁鵬;石田 博雄;熊澤 武志;廣澤 槙子;池田 賢一郎;藤城 雅也;藤田 健一;入戸野 晋;小林 一女;佐々木 康綱;高橋 春男;佐藤 啓造, 第62回昭和大学学士会総会, 28 Nov. 2015, 東京
Introduction -Innovation in Cancer Treatment-, FUJITA Ken-ichi, 日本薬物動態学会第30回年会, 14 Nov. 2015, 東京
Long-lasting inhibition of organic anion transporting polypeptide (OATP) 1B1 by endogenous uremic toxin indoxyl sulfate, KOGI Tatsuya;MASUO Yusuke;FUJITA Ken-ichi;KITAMURA Masanori;NAKAMICHI Noritaka;SASAKI Yasutsuna;KUNISHIMA Munetaka;KATO Yukio, 日本薬物動態学会第30回年会, 13 Nov. 2015, 東京
The estimation of drug interaction by pazopanib through the inhibition of UDP-glucuronosyltransferase (UGT) 1A1, IWASE Mariko;FUJITA Ken-ichi;NISHIMURA Yuki;OGUCHI Katsuji, 日本薬物動態学会第30回年会, 13 Nov. 2015, 東京
Comprehensive analysis of miRNA-variants in Japanese healthy subjects, non-small cell lung carcinoma and colorectal cancer patients, KATAYAMA Koki;GOTOH Saki;FUKAMI Tatsuya;ISHIDA Hiroo;KUBOTA Yutaro;KUSUMOTO Sojiro;FUJITA Ken-ichi;SASAKI Yasutsuna;NAKAJIMA Miki, 日本薬物動態学会第30回年会, 12 Nov. 2015, 東京
Mechanism underlying acquisition of dual resistance to EGFR & MET inhibitors by EGFR-mutant lung adenocarcinoma cells, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;TOYA Etsuko;KISHINO Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SAGARA Hironori;SASAKI Yasutsuna, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
Mechanism underlying acquisition of dual resistance to EGFR & MET inhibitors by EGFR-mutant lung adenocarcinoma cells, 山岡 利光;大森 亨;大場 基;外谷 衣都子;岸野 康成;村田 泰規;楠本 壮二郎;石田 博雄;大西 司;相良 博典;佐々木 康綱, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer, FUJITA Ken-ichi;YOSHINO Etsuko;KAWARA Kaori;MAEDA Kazuya;KUSUHARA Hiroyuki;SUGIYAMA Yuichi;YOKOYAMA Taro;KANETA Toshikado;ISHIDA Hiroo;SASAKI Yasutsuna, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
The effect of ErbB3 phosphorylation for miR-205 regulation in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyotaka;OGASAWARA Yuki, 第74回日本癌学会学術総会, 08 Oct. 2015, 名古屋
Personalized chemotherapy in breast cancer, 藤田 健一, 第9回日本緩和医療薬学会年会, 04 Oct. 2015, 横浜
A clinical pharmacokinetic microdosing study of docetaxel with Japanese cancer patients., FUJITA Ken-ichi;YOSHINO Etsuko;KAWARA Kaori;MAEDA Kazuya;KUSUHARA Hiroyuki;SUGIYAMA Yuichi;YOKOYAMA Taro;KANETA Toshikado;ISHIDA Hiroo;SASAKI Yasutsuna, The 40th European Society for Medical Oncology Annual Meeting (European Cancer Congress 2015), 27 Sep. 2015, Wien
Inhibition of metastasis of lung adenocarcinoma cells via the perturbed localization of Rab11FIP1 by PKCeta depletion, OHBA Motoi;TOYA Etsuko;YAMAOKA Toshimitsu;SASAKI Yasutsuna, 第13回日本臨床腫瘍学会集会, 17 Jul. 2015, 札幌
Appropriate dose of irinotecan in cancer patients with severe renal failure (SRF), FUJITA Ken-ichi;MASUO Yusuke;OKUMURA Hidenori;SASAKI Yasutsuna;KATO Yukio, 第13回日本臨床腫瘍学会学術集会, 16 Jul. 2015, 札幌
Roles of efflux transporters in regorafenib pharmacokinetics, 澁谷 俊紀;増尾 友佑;藤田 健一;中道 範隆;佐々木 康綱;加藤 将夫, 日本薬学会第135年会, 26 Mar. 2015, 神戸
Optimization of the dose of irinotecan in cancer patients with severe renal failure (SRF) based on physiologically-based pharmacokinetic (PBPK) model., FUJITA Ken-ichi;MASUO Yusuke;OKUMURA Hidenori;SASAKI Yasutsuna;KATO Yukio, 116th American Society for Clinical Pharmacology and Therapeutics annual meeting, 05 Mar. 2015, New Orleans
Determination of tegafur and 5-fluorouracil in tear by HILIC-MS/MS., OBUCHI Ritsuko;LEE Xiao-Pen;HIROSAWA Makiko;ISHIDA Hiroo;FUJITA Ken-ichi;NITTONO Susumu;YOSHIDA Masato;SASAKI Yasutsuna;SATO Keizo;TAKAHASHI Haruo, Asia-ARVO (The Association for Research in Vision and Ophtalmology) 2015, 18 Feb. 2015, Yokohama
Simple blood test for diagnosis of gastrointestinal and pancreas cancer using surface-enhanced Raman scattering, ITO Hiroaki;HASEGAWA Katsuyuki;HASEGAWA Yuuki;KIMURA Satoshi;ONIMARU Manabu;OHMORI Tohru;IKEDA Haruo;SAITO Mitsuo;KITAMURA Yohei;SATO Chiaki;GOMI Kuniyo;SAKAUE Satoshi;ISOZAKI Masayuki;MATSUKAWA Masaaki;INOUE Haruhiro, American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium, 15 Jan. 2015, Chicago
Increase in plasma unbound concentration and decrease in protein binding of SN-38 in cancer patients with severe renal failure, 藤田 健一;増尾 友祐;奥村 英典;砂川 優;嶋田 顕;河原 香織;秋山 祐子;佐々木 康綱;加藤 将夫, 第35回日本臨床薬理学会学術総会, 04 Dec. 2014, 松山
Inhibition of OATP1B1-mediated hepatic transport by uremic toxins, 小木 達也;増尾 友佑;藤田 健一;北村 正典;奥村 英典;中道 範隆;佐々木 康綱;国嶋 崇隆;加藤 将夫, 第36回生体膜と薬物の相互作用シンポジウム, 21 Nov. 2014, 徳島
The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyoataka;OGASAWARA Yuki, 第73回日本癌学会学術総会, 27 Sep. 2014, 横浜
Change in plasma protein binding of SN-38, an active metabolite of irinotecan, in cancer patients with severe renal failure (SRF), FUJITA Ken-ichi;OKUMURA Hidenori;MASUO Yusuke;SUNAKAWA Yu;SHIMADA Ken;KAWARA Kaori;AKIYAMA Yuko;SASAKI Yasutsuna;KATO Yukio, The 39th European Society for Medical Oncology annual meeting, 27 Sep. 2014, Madrid
Association of pharmacokinetics or pharmacogenomics with toxicity of erlotinib in patients with recurrent advanced non-small cell lung cancer., HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OKUDA Kentaro;OHNISHI Tsukasa;OHMORI Tohru;SASAKI Yasutsuna;TAMURA Atsuhisa;OHTA Ken, The 39th European Society for Medical Oncology annual meeting, 27 Sep. 2014, Madrid
EGFR transactivation by TNF protects EGFR-TKI, gefitinib induced pulmonary injury in SP-C/TNF transgenic mice, YAMAOKA Toshimitsu;OHMORI Tohru;OHKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;HIROSE Takashi;OHNISHI Tsukasa;SASAKI Yasutsuna, 第73回日本癌学会学術総会, 26 Sep. 2014, 横浜
PKCη controls the proliferation of lung adenocarcinoma cells via EGFR and MET endocytic trafficking., OHBA Motoi;TOYA Etsuko;YAMAOKA Toshimitsu;OHMORI Tohru;SASAKI Yasutsuna, 第73回日本癌学会学術総会, 25 Sep. 2014, 横浜
Development of Simple Blood Test for Diagnosis of Gastrointestinal and Pancreas Cancer Using Biochip, ITO Hiroaki;HASEGAWA Katsuyuki;HOSOMICHI Kazuyoshi;HASEGAWA Yuuki;INOUE Itsuro;KIMURA Satoshi;OHMORI Tohru;KUDO Shin-ei;MATSUKAWA Masaaki;INOUE Haruhiro, 第73回日本癌学会学術総会, 25 Sep. 2014, 横浜
Association of pharmacokinetics or pharmacogenomics with toxicity of erlotinib in patients with advanced NSCLC, HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;SHIRAI Takao;SUGIYAMA Tomohide;NAKASHIMA Masanao;OHMORI Tohru;SASAKI Yasutsuna;TAMURA Atsuhisa;OHTA Ken, 第12回日本臨床腫瘍学会学術集会, 19 Jul. 2014, 福岡
PKCη controls the proliferation of lung adenocarcinoma cells via EGFR and MET endocytic trafficking, OHBA Motoi;TOYA Etsuko;YAMAOKA Toshimitsu;OHMORI Tohru;KUROKI Toshio;SASAKI Yasutsuna, 第12回日本臨床腫瘍学会学術集会, 18 Jul. 2014, 福岡
Involvement of protein kinase C eta in the migration and invasion of human lung adenocarcinoma cells, 外谷 衣都子;大場 基;山岡 利光;大森 亨;佐々木 康綱, 第12回日本臨床腫瘍学会学術集会, 18 Jul. 2014, 福岡
Tivantinib, shows a synergistic growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein, OHMORI Tohru;YAMAOKA Toshimitsu;TOYA Etsuko;OHBA Motoi;KOIZUMI Fumiaki;NISHIO Kazuto;AKINAGA Shiro, 第12回日本臨床腫瘍学会学術集会, 17 Jul. 2014, 福岡
TNF transactivation of EGFR protects EGFR-TKI induced pulmonary injury in SPC-TNF transgenic mice, 山岡 利光;外谷 衣都子;大場 基;大木 康成;村田 泰規;楠本 壮二郎;石田 博雄;大森 亨;佐々木 康綱, 第12回日本臨床腫瘍学会学術集会, 17 Jul. 2014, 福岡
Pharmacokinetics of docetaxel in a clinical microdosing study with Japanese patients with cancer, 藤田 健一;吉野 悦子;河原 香織;前田 和哉;杉山 雄一;佐々木 康綱, 第12回日本臨床腫瘍学会学術集会, 17 Jul. 2014, 福岡
An internally and externally validated nomogram to predict severe neutropenia in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens., ICHIKAWA Wataru;UEHARA Keisuke;MINAMIMURA Keisuke;TANAKA Chihiro;TAKII Yasumasa;MIYAUCHI Hideaki;SADAHIRO Sotaro;FUJITA Ken-ichi;MORIWAKI Toshikazu;NAKAMURA Masato;TAKAHASHI Takehiro;TSUJI Akihito;SHINOZAKI Katsunori;MORITA Satoshi;ANDO Yuichi;OKUTANI Yukihiro;SUGIHARA Masahiro;SUGIYAMA Toru;OHASHI Yasuo;SAKATA Yuh, 50th American Society of Clinical Oncology annual meeting, 31 May 2014, Chicago
非小細胞肺癌におけるエルロチニブとゾレドロン酸併用療法の有用性に関する後方視的解析, 大木 康成;廣瀬 敬;白井 崇生;村田 泰規;杉山 智英 ;楠本 壮二郎;石田 博雄;中嶌 賢尚;山岡 利光;奥田 健太郎;大西 司;大森 亨;相良 博典, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
Pharmacokinetics, pharmacogenetics and toxicity of erlotinib in patients with non-small cell lung cancer, 廣瀬 敬;藤田 健一;楠本 壮二郎;白井 崇生;村田 泰則;大木 康成;杉山 智英;石田 博雄;中嶌 賢尚;山岡 利光;奥田 健太郎;大西 司;大森 亨;佐々木 康綱;田村 厚久;大田 健, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
小細胞肺癌患者における末梢血がん細胞数と予後の検討, 白井 崇生;廣瀬 敬;大木 康成;村田 泰規;楠本 壮二郎;杉山 智英;石田 博雄;中鴬 賢尚;山岡 利光;奥田 健太郎;大西 司;大森 亨;相良 博典, 第54回日本呼吸器学会学術講演会, 25 Apr. 2014, 大阪
Comtribution of miR-205 in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro ;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyotaka;OGASAWARA Yuki, The 105th Annual Meeting of the American Association for Cancer Research, 07 Apr. 2014, San Diego
TNF transactivation of EGFR protects EGFR-TKI, gefitinib induced pulmonary epithelial cell apoptosis and injury in TNF transgenic mice., YAMAOKA Toshimitsu;OKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;TOYA Etsuko;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori;SASAKI Yasutsuna, 105th American Association for Cancer Research annual meeting, 07 Apr. 2014, San Diego
Basic and clinical studies to establish optimal dosing of irinotecan in cancer patients with severe renal failure who were undergoing dialysis., 藤田 健一, 第47回制癌剤適応研究会, 07 Mar. 2014, 名古屋
Novel methodology of integrated omics analysis by using Surface Enhanced Raman Scattering (SERS): A Preliminary Study, ITO Hiroaki;INOUE Haruhiro;SANDO Norimasa;HASEGAW Katsuyuki;HASEGAWA Yuki;OHMORI Tohru;KIMURA Satoshi;KUDO Shin-ei, 第72回日本癌学会学術総会, 04 Oct. 2013, 横浜
The characteristics of dual resistance to EGFR & MET inhibitors in pulmonary adenocarcinoma, PC-9 cells, YAMAOKA Toshimitsu;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;OKUDA Kentaro;TOYA Etsuko;OHBA Motoi;OHMORI Tohru;SASAKI Yasutsuna, 第72回日本癌学会学術総会, 03 Oct. 2013, 横浜
Clinical benefit of 2nd EGFR-TKI retreatment on overall survival in patients with advanced non-small cell lung cancer, NAKASHIMA Masanao;HIROSE Takashi;OHKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;OKUDA Kentaro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa, 第11回日本臨床腫瘍学会学術集会, 30 Aug. 2013, 仙台
The characteristics of an acquired dural resistance to EGFR & MET inhibitors in non-small cell lung cancer, harboring active mutation of EGFR, YAMAOKA Toshimitsu;ICHIHASHI Yoko;MURATA Yasunori;OKI Yasunari;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;OKUDA Kentaro;HIROSE Takashi;OHNISHI Tsukasa;OHMORI Tohru, AACR 104th Annual Meeting 2013, 10 Apr. 2013, Washington, DC
A novel c-MET inhibitor, tivantinib, shows an additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via its recycling pathway, OHMORI Tohru;KANOME Tomoko;YAMAOKA Toshimitsu;HIROSE Takashi;KOIZUMI Fumiaki;NISHIO Kazuto;AKINAGA Shiro, 19th International Charles Heidelberger Symposium on Cancer Research, 14 Feb. 2013, Kagoshima
Carboplatin+Paclitaxel+Bevacizumabによる化学療法中にIII度房室ブロックをきたした肺腺癌症例, 白井 崇生;廣瀬 敬;大木 康成;村田 泰規;楠本 壮二郎;杉山 智英;石田 博雄;中嶌 賢尚;奥田 健太郎;大西 司;足立 満;山岡 利光;大森 亨, 第53回日本肺癌学会総会, 08 Nov. 2012, 岡山
進展型小細胞肺癌の生存期間に対するアムルビシンの影響に関する検討., 石田 博雄;大木 康成;村田 泰規;石田 孔子;楠本 壮二郎;杉山 智英;白井 崇生;中嶌 賢尚;山岡 利光;奥田 健太郎;大西 司;大森 亨;廣瀬 敬, 第50回日本癌治療学会学術集会, 25 Oct. 2012, 横浜
Cancer vaccination trial novel multiple peptides in previously treated advanced non-small-cell lung cancer (NSCLC), 廣瀬 敬;野田 秀裕;奥田 健太郎;阿部 誠治;大戸 祐治;杉山 智英;石田 博雄;白井 崇生;中嶌 賢尚;山岡 利光;大森 亨;吉田 浩二;中村 祐輔, 第71回日本癌学会学術総会, 19 Sep. 2012, 札幌
HSP70 causes EGFR-TKIs resistance in a mutant EGFR expressed non-small cell lung cancer, OHMORI Tohru;YAMAOKA Toshimitsu;ICHIHASHI Yoko;HIROSE Takashi;SAIJO Nagahiro, 第10回日本臨床腫瘍学会学術集会, 27 Jul. 2012, 大阪
Cancer Vaccination trial with novel multiple peptides in previously treated advanced non-small cell lung cancer., HIROSE Takashi;NODA Hidehiro;OKUDA Kentaro;ABE Seiji;OTO Yuji;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHMORI Tohru;YOSHIDA Koji;NAKAMURA Yusuke;ADACHI Mitsuru, 2012 Annual Meeting of the American Society of Clinical Oncology, 01 Jun. 2012, Chicago
HSP 70 may cause EGFR-TKIs-resistance due to inhibit drug binding to EGFR in the cells that expressed mutant EGFR., OHMORI Tohru;KADOFUKU Tsuyoki;ICHIHASHI Yoko;YAMAOKA Toshimitsu;HIROSE Takashi;ADACHI Mitsuru;SAIJO Nagahiro, AACR 103rd Annual Meeting 2012, 02 Apr. 2012, Chicago
Specific epidermal growth factor receptor autophosphorylation sites promote epithelial cell chemotaxis and restitution., YAMAOKA Toshimitsu;FREY Mark;POLK D Brent;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;OKUDA Kentaro;OHNISHI Tsukasa;HIROSE Takashi;OHMORI Tohru;ADACHI Mitsuru, AACR 103rd Annual Meeting 2012, 02 Apr. 2012, Chicago